Screening For B-19 Virus Should Be Limited To Plasma Products - BPAC
This article was originally published in The Gray Sheet
FDA should not require blood product manufacturers to conduct clinical effectiveness studies or require an investigational new drug exemption for the nucleic acid testing (NAT) of plasma for Parvovirus B-19, members of the agency's Blood Products Advisory Committee agreed at their Sept. 16 meeting in Bethesda, Maryland.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.